ClearPoint Neuro beglückwünscht seinem Partner AviadoBio zur Behandlung des ersten Patienten in der klinischen Studie ASPIRE-FTD, in der AVB-101 für frontotemporale Demenz mit GRN-Mutationen evaluiert wird
17 avr. 2024 15h21 HE
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Kalifornien, April 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (das „Unternehmen“), ein globales Unternehmen für Geräte, Zellen und Gentherapie, das präzise...
ClearPoint Neuro félicite son partenaire AviadoBio pour son premier patient traité dans le cadre de son essai clinique ASPIRE-FTD évaluant l’AVB-101 dans la démence fronto-temporale avec mutations du gène GRN
17 avr. 2024 15h21 HE
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Californie, 17 avr. 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq : CLPT) (la « Société »), une société mondiale spécialisée dans les dispositifs, de thérapie cellulaire et...
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
16 avr. 2024 16h05 HE
|
ClearPoint Neuro, Inc.
ClearPoint Neuro platform and SmartFlow Cannula to be used by all centers in AviadoBio's ASPIRE-FTD gene therapy trial treating frontotemporal dementia
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
19 mars 2024 08h07 HE
|
ClearPoint Neuro, Inc.
ClearPoint Neuro's partner's completed BLA Submission for Upstaza™ would be first disease-modifying treatment for AADC Deficiency in the US.
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results
12 mars 2024 16h05 HE
|
ClearPoint Neuro, Inc.
ClearPoint Neuro reports 32% growth in fourth quarter as compared to fourth quarter of 2022. Biologics revenue increased 49% YOY.
Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System
11 mars 2024 08h00 HE
|
ClearPoint Neuro, Inc.
ClearPoint Neuro announces peer-reviewed publication showing correlation of software lesion size to histopathology, only FDA-cleared laser with correlation
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024
01 mars 2024 16h05 HE
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation...
ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock
29 févr. 2024 08h00 HE
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to...
ClearPoint Neuro Launches Proposed Public Offering of Common Stock
28 févr. 2024 16h45 HE
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to...
ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model
21 févr. 2024 16h05 HE
|
ClearPoint Neuro, Inc.
ClearPoint Neuro announces FDA Clearance and first-in-human cases using 2.2 Software with integrated Maestro Brain Modeling, and publication in NeuroImage